Wednesday, October 22, 2014 Last update: 11:33 PM - Covering Large & Obscure Tech Companies Since 1996

InSite Vision to Report First Quarter 2014 Financial Results on May 14, 2014

Companies mentioned in this article: InSite Vision Incorporated

ALAMEDA, Calif. -- (BUSINESS WIRE) -- InSite Vision Incorporated (OTCBB: INSV) announced that it will report financial results for the quarter ended March 31, 2014 on Wednesday, May 14, 2014.

InSite Vision management will host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss first quarter 2014 financial results and to review recent accomplishments and upcoming milestones. Investors will be invited to ask questions following management’s prepared remarks.

Analysts and investors can participate in the conference call by dialing 888-680-0890 for domestic callers and 617-213-4857 for international callers using the pass code 82284459. Interested parties are encouraged to pre-register to avoid delays at A telephone replay will be available for two weeks following the conclusion of the call by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers using the pass code 68069625.

The conference call will also be webcast and available on the Investor Relations page of the company's website at Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required.

A press release detailing first quarter 2014 financial results will be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.

About InSite Vision

InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.

The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Akorn Pharmaceuticals; and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals International. InSite Vision is preparing a new drug application (NDA) for the commercial approval by the U.S. Food & Drug Administration (FDA) of BromSite™ for the prevention of pain and inflammation associated with ocular surgery. InSite Vision is also in discussions with the FDA regarding the potential advancement of two novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus and DexaSite for the treatment of eye infections, and has a pipeline of earlier-stage product candidates based on its platform technologies. For further information on InSite Vision, please visit

AzaSite® and DuraSite® are registered trademarks of InSite Vision Incorporated.

AzaSite Plus, BromSite and DexaSite are trademarks of InSite Vision Incorporated.

BESIVANCE® is a registered trademark of Bausch + Lomb Incorporated.

Copyright © Business Wire 2014

InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
Media and Investor inquiries
BCC Partners
Michelle Corral, 415-794-8662
Karen L. Bergman, 650-575-1509